This is a news story, published by CNBC, that relates primarily to Neurocrine Biosciences news.
For more Neurocrine Biosciences news, you can click here:
more Neurocrine Biosciences newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
revenue beat estimates. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest earnings news, quarter revenue forecast news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
revenue guidanceCNBC
•86% Informative
Adobe shares plunged more than 10% after the software company issued soft guidance.
Oracle advanced nearly 6% after raising its revenue guidance.
RH surged nearly 19% after posting a top- and bottom-line beat in for the fiscal second quarter .
Neurocrine Biosciences reported that its investigational drug luvadaxistat failed to reach primary endpoints in a phase 2 study.
VR Score
91
Informative language
95
Neutral language
20
Article tone
formal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Affiliate links
no affiliate links